Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience

We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%. Venetoclax was well‐tolerated in 62.5% of the patients. Ven/HMA provides a benefit particularl...

Descripción completa

Detalles Bibliográficos
Autores principales: Roldán Pérez, Alicia, Vázquez Paganini, Juan Andrés, Penalva Moreno, M. José, Giménez Mesa, Eugenio, Vilches Moreno, Alba Sara, Nuñez‐Torrón Stock, Claudia, Herráez García, Regina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309735/
https://www.ncbi.nlm.nih.gov/pubmed/35898750
http://dx.doi.org/10.1002/ccr3.6116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309735/
https://www.ncbi.nlm.nih.gov/pubmed/35898750
http://dx.doi.org/10.1002/ccr3.6116

Ejemplares similares